此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes

2018年9月4日 更新者:Sansum Diabetes Research Institute

Feasibility Study to Assess the Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes on Sensor Augmented Insulin Pump

This clinical trial will identify exercise-related and emotional stress related effects on glycemic control in patients with type 1 diabetes using sensor-augmented pump (SAP) therapy.

研究概览

详细说明

Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.

研究类型

介入性

注册 (实际的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Santa Barbara、California、美国、93111
        • Sansum Diabetes Research Institute
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18-75 years
  • Clinical diagnosis, based on investigator assessment, of T1D for at least one year and using insulin for at least 1 year.
  • Using an insulin pump for diabetes therapy for at least 3 months
  • Demonstration of proper mental status and cognition for the study
  • Non-smoker
  • If not currently using CGM, willing to use CGM during the study
  • An understanding of and willingness to follow the protocol and sign the informed consent

Exclusion Criteria:

  • Admission for diabetic ketoacidosis in the 6 months prior to enrollment unless study team feels the subject is appropriate for study given complete clinical context for subject
  • Severe hypoglycemia resulting in seizure or loss of consciousness > once in the 6 months prior to enrollment
  • History of a seizure disorder (except hypoglycemic seizure), unless written clearance is received from a neurologist and not currently on a seizure medication
  • Cystic fibrosis
  • Unstable coronary artery disease or heart failure, unless written clearance is received from a cardiologist or primary care provider
  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:

    1. Inpatient psychiatric treatment in the past 6 months
    2. Presence of a known adrenal disorder or chronic oral steroid therapy
    3. Abnormal liver function test results (Transaminase >3 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
    4. Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2);
    5. Active gastroparesis (defined actively being treated with medications)
  • If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
  • Abuse of alcohol or recreational drugs
  • Pregnancy
  • Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis).
  • Uncontrolled arterial hypertension (Resting diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg) at the time of screening
  • Uncontrolled microvascular complications such as current active proliferative diabetic retinopathy defined as proliferative retinopathy requiring treatment (e.g. laser therapy) in the past 12 months.
  • A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Observation of Exercise
Observation During Exercise and Stress

Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.

Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl
大体时间:5 Weeks
Examine the impact of Stress and Exercise on CGM Glucose Levels, determining how these factors affect time within target glucose range 70-180 mg/dl. Correlate these factors that influence glycemic control to inform future algorithm development for an artificial pancreas (AP) device to better handle exercise and stress related events to be used in a future study.
5 Weeks

次要结果测量

结果测量
措施说明
大体时间
CGM Glucose Levels 70-180 mg/dl
大体时间:5 Weeks
CGM Glucose Levels, within target range 70-180 mg/dl
5 Weeks
CGM Glucose Levels less than 70 mg/dl
大体时间:5 Weeks
CGM Glucose Levels, less than 70 mg/dl
5 Weeks
CGM Glucose Levels greater than 180 mg/dl
大体时间:5 Weeks
CGM Glucose Levels, greater than 180 mg/dl
5 Weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yogish C Kudva, MD、Mayo Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年11月1日

初级完成 (实际的)

2018年8月31日

研究完成 (实际的)

2018年8月31日

研究注册日期

首次提交

2017年10月3日

首先提交符合 QC 标准的

2017年10月6日

首次发布 (实际的)

2017年10月12日

研究记录更新

最后更新发布 (实际的)

2018年9月5日

上次提交的符合 QC 标准的更新

2018年9月4日

最后验证

2018年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

1 型糖尿病的临床试验

订阅